[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scleroderma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scleroderma":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,50,95,124,154,181,214,243,279,308,336,356,381,412,440,468,490,514,539,555,580,607,632,1036,1064],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100641434","phase-1-a-phase-12-study-of-pro-203-in-healthy-volunteers-and-participants-with-systemic-sclerosis-100641434",false,"NCT07641634","A Phase 1\u002F2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.","A Two-part, Phase 1\u002F2, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study of PRO-203 in Healthy Adult Volunteers Followed by an Open-label, Single-ascending-dose With Priming Study of PRO-203 in Participants With Systemic Sclerosis","Key Inclusion Criteria (All Participants)\n\n* Is male or female, age 18 to 65 years, inclusive, at Screening.\n* Able to provide Informed Consent.\n* Absolute B cell count \\> 25 cells\u002FuL.\n\nAdditional Inclusion for Part 1 (Closed to Enrollment)\n\n* In good general health, determined by no clinically significant findings in the of the investigator from medical history, physical examination, 12-lead ECG, clinical laboratory findings, and vital signs at Screening and Day -1 (participants with Gilbert's disease with associated abnormalities of liver function tests are eligible for enrollment).\n* Up to date vaccination status per local guidelines (including but not limited to influenza vaccine, COVID booster and hepatitis B vaccine).\n\nAdditional Inclusion for Part 2\n\n* Fulfill 2013 ACR\u002F EULAR criteria for classification of SSc with a total score of ≥ 9.\n* Active disease defined as at least two of the following at screening:\n* Disease duration ≤ 2 years (since onset of first-non-Raynaud-symptom), or\n* Elevated acute phase reactant levels (CRP ≥ 6 mg\u002FL, erythrocytes sedimentation rate \\[ESR\\] ≥ 28 mm\u002F1h, or platelet count ≥ 330,000\u002FµL), or\n* Baseline mRSS ≥10 with evidence of progression, defined as mRSS increase at least 3 units, or involvement of 1 new body area and mRSS increase at least 2 units, or involvement of 2 new body areas (each within the previous 6 months), or\n* ≥ 1 tendon friction rub, or\n* Elevation of CK or aldolase \\> 2 × the upper limit of normal (ULN) consistent with SSc-related myopathy, or\n* Progressive fibrosing interstitial lung disease (ILD) as defined by at least one of the following criteria at any time within the prior 2 years:\n\n  1. relative decline in forced vital capacity (FVC) % predicted ≥ 10%, or\n  2. relative decline in FVC % predicted ≥ 5% to \\\u003C10% and worsened respiratory symptoms, or\n  3. relative decline in FVC % predicted ≥ 5% to \\\u003C10% and increased extent of fibrosis on high-resolution computed tomography (HRCT), or\n  4. worsened respiratory symptoms and increased extent of fibrosis on HRCT\n* Intolerant or refractory to at least 1 line of standard therapy, including methotrexate, azathioprine, IVIG, mycophenolic acid derivatives, cyclophosphamide, TNF-inhibitors, rituximab, or tocilizumab.\n\nKey Exclusion Criteria (All Participants)\n\n* Any clinically significant underlying illness in the opinion of the investigator.\n* Active infection within 4 weeks prior to screening. Participants receiving IV antibiotics or having received IV antibiotics within 14 days prior to enrollment are excluded.\n* Positive QuantiFERON-Gold TB test at screening.\n* Plan to receive live, attenuated vaccine after signing ICF (inactive vaccines, such as the flu vaccine, are allowed).\n* Evidence of malignant disease or malignancies diagnosed within the previous 5 years (except for treated local basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that had been excised and cured).\n* Currently enrolled in another investigational device or drug study, or less than 30 days or 5 half-lives of the prior investigational agent (whichever is longer) have passed since ending another investigational device or drug study or plans to enroll in another investigational device or drug study during the course of this study.\n* Social smokers e.g. up to 10 cigarettes per week (or equivalent amounts of nicotine containing products) and willing to abstain during inpatient stay, are allowed\n\nAdditional Exclusion Criteria for Part 1 (Closed to Enrollment)\n\n* Use of any prescription medication within 14 days and OTC medications, vitamins, herbal medications (e.g., St. John's wort), or cannabis, except for contraceptive medications and as needed (prn) acetaminophen\u002Fparacetamol (not exceeding 2 grams\u002Fday) within 7 days prior to administration of the study drug and throughout the study.\n\nAdditional Exclusion Criteria for Part 2\n\n* Rheumatic autoimmune disease other than SSc.\n* Positive anti-centromere antibodies.\n* Pulmonary disease with FVC ≤ 45% of predicted, or DLCO ≤ 35% of predicted.\n* Class 2 or higher pulmonary arterial hypertension or evidence of other moderately severe pulmonary disease.\n* Renal crisis within 6 months prior to Screening.\n* Prior treatment with cellular immunotherapy (eg, CAR-T) or gene therapy product directed at any target.\n* Previous treatment with chlorambucil, bone marrow transplantation, or total lymphoid irradiation.\n* Previous treatment with thalidomide, anti-thymocyte globulin, plasmapheresis, or extracorporeal photopheresis.\n* Unable to washout current immunosuppressive therapy within 2 months\n* Has received anti-CD19 or CD20 therapies, within 6 months prior to start of therapy\n* Plan to receive live or live-attenuated vaccines within 8 weeks prior to first dose of study drug and during treatment until B cell reconstitution to 80% of baseline (inactive vaccines, such as the flu vaccine, are allowed)","ALL","18 Years","65 Years",{"count":21,"type":22},44,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","A two-part study of PRO-203 administered subcutaneously in healthy adult volunteers and participants with Systemic Sclerosis (SSc).",[29,30,31,32],"Healthy Volunteers","Systemic Sclerosis (SSc)","Scleroderma, Systemic","Scleroderma",[34,35,32,36],"Systemic sclerosis","SSc","B cell depletion","RECRUITING","2026-06-16",{"date":40,"type":41},"2026-06-18","ACTUAL",{"date":43,"type":41},"2025-10-27",{"date":45,"type":22},"2028-01",{"name":47,"class":48},"Prolium Bioscience, Inc","INDUSTRY",3,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":69,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100592260","phase-2-allonk-an-allogeneic-non-genetically-modified-cord-blood-derived-nk-cell-therapy-in-combination-with-rituximab-studied-in-relapsing-forms-of-b-cell-dependent-rheumatologic-diseases-100592260","NCT06991114","AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.","An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases","For Subjects with Refractory Rheumatoid Arthritis (RA):\n\n* Documented diagnosis of RA, meeting the 2010 ACR\u002FEULAR classification criteria.\n* Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive.\n* High-sensitivity C-reactive protein (hs-CRP) \\> 3 mg\u002FL or Erythrocyte Sedimentation Rate (ESR) \\> 28 mm\u002Fhr.\n* Have had prior treatment for a period of at least 12 weeks with a biologic disease modifying anti-rheumatic drug and were deemed refractory by the treating physician.\n* Minimum of six swollen joint counts (SJC) and six tender joint counts (TJC) according to joint assessment.\n\nFor subjects with Sjögren's Disease (SjD)\n\n* Prior diagnosis of Primary SjD as per 2016 ACR\u002FEULAR criteria with confirmatory diagnosis in the 24 weeks preceding screening.\n* Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) \\> 6.\n* Salivary Flow Rate \\> 0.1 mL\u002Fmin on stimulation.\n\nFor subjects with Idiopathic Inflammatory Myopathies (IIMs)\n\n* Presence of a positive autoantibody (ANA \\>1:80 or RNP or SSA\u002FSSB or other myositis specific autoantibodies.\n* Refractory IIM as defined by inadequate response\u002Fintolerance to at least 3 months of glucocorticoids and\u002For at least one other immunosuppressive.\n* Muscle biopsy or muscle MRI to confirm IIM diagnosis, where applicable, within 12 months prior to enrollment.\n\nFor Subjects with Systemic Sclerosis (SSc)\n\n* Diagnosis of SSc in accordance with the ACR\u002FEULAR 2013 classification.\n* Modified Rodnan skin score (mRSS) \\> 10.\n* Initial confirmatory diagnosis within 8 years of screening.\n* Refractory SSc as defined by inadequate response\u002Fintolerance to at least 3 months of glucocorticoids and\u002For at least one other immunosuppressive.",{"count":58,"type":22},90,[26],"A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.",[62,63,30,64,65,66,32,67,68],"Refractory Rheumatoid Arthritis (RA)","Idiopathic Inflammatory Myopathies (IIMs)","Rheumatoid Arthritis (RA","IIM","Myositis","Sjogren Syndrome","Sjogrens Disease",[70,71,72,73,74,75,76,77,78,79,80,81,82,83,84],"Refractory Rheumatoid Arthritis","AlloNK","Idiopathic Inflammatory Myopathies","Systemic Sclerosis","Sjögren's Disease","Refractory RA","Cell Therapy","Allogeneic NK Cells","Allogeneic Cell Therapy","non-genetically modified","rituximab","cord blood cells","ADCC enhancement","outpatient","community","2026-05-20",{"date":87,"type":41},"2026-05-22",{"date":89,"type":41},"2025-07-09",{"date":91,"type":22},"2029-01",{"name":93,"class":48},"Artiva Biotherapeutics, Inc.",52,{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100541355","phase-1-reset-ssc-an-open-label-study-to-evaluate-the-safety-and-efficacy-of-caba-201-a-cd19-car-t-cell-therapy-in-subjects-with-systemic-sclerosis-100541355","NCT06328777","RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis","A Phase 1\u002F2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis","Inclusion Criteria:\n\n* Age ≥18 and ≤75\n* A clinical diagnosis of SSc, based on the 2013 American College of Rheumatology and European League Against Rheumatism classification criteria.\n* Early active disease\n* Evidence of significant skin, pulmonary, renal, or cardiac involvement\n\nExclusion Criteria:\n\n* Contraindication to leukapheresis\n* History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites\n* Active infection requiring medical intervention at screening visit\n* Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.\n* Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures\n* Severe lung or cardiac impairment\n* Previous CAR T cell therapy\n* Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","75 Years",{"count":104,"type":22},12,[25,26],"RESET-SSc: A Phase 1\u002F2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis",[73,32],[109,110,111,112,113],"CABA-201","autoimmune disease","anti-CD19 CAR-T therapy","systemic sclerosis","scleroderma","2026-05-13",{"date":116,"type":41},"2026-05-14",{"date":118,"type":41},"2024-07-02",{"date":120,"type":22},"2029-07",{"name":122,"class":48},"Cabaletta Bio",10,{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":131,"sex":17,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100347151","skeletal-muscle-function-in-interstitial-lung-disease-100347151","NCT03800017","Skeletal Muscle Function in Interstitial Lung Disease","Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease","Inclusion Criteria for ILD Patients:\n\n* Age 40-80 years (inclusive)\n* A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses\n* Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis\n* Appropriate candidate for pulmonary rehabilitation\n* 6 minute walk distance 50m or more\n* Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air\n* Clinically stable for the preceding 6 weeks\n* Can fluently read and write in English\n\nInclusion Criteria for Healthy Controls:\n\n* Age 40-80 (inclusive)\n* Normal pulmonary function (80-120% predicted)\n* No lung or cardiovascular disease\n* Can fluently read and write in English\n\nExclusion Criteria for the ILD patients:\n\n* Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)\n* Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and\u002For oxygenation\n* Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%\n* Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program\n* Use of prednisone greater than 10 mg\u002Fday for more than 2 weeks within 3 months of the first study visit\n* Significant emphysema (less than 10% volume on HRCT or FEV1\u002FFVC less than 0.70)\n\nExclusion Criteria for Healthy Controls:\n\n* Currently smoking or previously smoked more than 10 pack-years\n* Any medical conditions that prevents them for exercising safely\n* Cardiac pacemaker or any metal or electronic inside the body",true,"40 Years","80 Years",{"count":135,"type":22},40,[137],"NA","Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.",[140,141,142,32,143],"Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis","Hypersensitivity Pneumonitis","Nonspecific Interstitial Pneumonia",{"date":145,"type":41},"2026-05-15",{"date":147,"type":41},"2024-08-07",{"date":149,"type":22},"2026-12-31",{"name":151,"class":152},"University of British Columbia","OTHER",1,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":153},"100577655","phase-1-efficacy-and-safety-of-hn2301-in-autoimmune-diseasesaids-100577655","NCT06801119","Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）","Dose-escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of HN2301 in Patients With Autoimmune Diseases Including Systemic Lupus Erythematosus（SLE）, Systemic Sclerosis (SSc) and Rheumatoid Arthritis （RA）","SLE，SSc，RA","Inclusion Criteria:\n\n* Patients aged between 18 and 69 (inclusive), of any gender;\n* Appropriate bone marrow, coagulation, cardiopulmonary, liver, and kidney functions. Bone marrow function: ANC ≥1.5×10\\^9\u002FL, ALC ≥0.8×10\\^9\u002FL, Hb ≥80g\u002FL. No use of transfusions and growth factors allowed within 7 days prior to screening to meet these requirements. Coagulation function: INR or APTT ≤1.5×ULN. Cardiac function: Echocardiography (ECHO) assessment of left ventricular ejection fraction (LVEF) ≥40%. Lung function: ≤CTCAE grade 1 dyspnea and SpO2 ≥92% (measured by pulse oximetry) while breathing indoor air. Liver function: ALT and AST ≤2.5×ULN, total bilirubin \\\u003C2.0mg\u002FdL (Gilbert syndrome subjects total bilirubin \\\u003C3.0mg\u002FdL). Kidney function: defined as creatinine clearance rate (Cockcroft-Gault) ≥50mL\u002Fmin without need for fluid assistance;\n* Non-pregnant\u002Fnon-lactating participants, willing to adopt contraceptive measures within 12 months after drug infusion;\n* Diagnosed with SLE according to the 2019 EULAR\u002FACR SLE diagnostic criteria; A history of SLE for at least 6 months, having used a stable standard treatment regimen for at least 8 weeks; Oral corticosteroids are prednisone (or equivalent drug) ≥7.5mg\u002Fday and ≤30mg\u002Fday. At least two immunosuppressants have been used in a standardized manner (including hydroxychloroquine); Screening period tests meet: positive blood antinuclear antibody (ANA), and\u002For positive anti-ds-DNA antibodies, and\u002For hypocomplementemia;\n* SSc-meets the classification criteria of ACR and EULAR, 10-35 in mRSS score;\n* RA-meets the classification criteria of ACR and EULAR, DAS28-ESR\\>3.2, ACPA possitive.\n\nExclusion Criteria:\n\n* Individuals with positive Hepatitis B surface antigen (HBsAg) and\u002For Hepatitis B core antibody (HBcAb), and Hepatitis B virus (HBV) DNA positivity or titers above the detection threshold; those with positive Hepatitis C virus (HCV) antibodies and HCV RNA positivity or titers above the detection threshold; individuals with Human Immunodeficiency Virus (HIV) antibodies positivity, CMV DNA positivity or above the detection limit; those with positive syphilis antigen or antibodies;\n* Presence of other uncontrolled active infections;\n* History of major organ transplantation (such as heart, lung, liver, kidney) or bone marrow\u002Fhematopoietic stem cell transplantation;\n* Pregnant or breastfeeding women;\n* Receiving any mRNA-LNP product or other LNP medications within the past two years;\n* History of any of the following cardiovascular diseases within the last 6 months before screening: Class III or IV heart failure defined by the New York Heart Association (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac diseases;\n* History of live vaccine administration within the last 30 days;\n* Individuals with asthma, severe allergies;\n* Other conditions deemed inappropriate for participation in this clinical study by the investigator.","69 Years",{"count":164,"type":22},30,[25],"This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease（AID）",[168,32,169],"Systemic Lupus Erythematosus","Rheumatoid Arthritis",[171],"SLE, SSc,RA","2026-04-26",{"date":174,"type":41},"2026-04-28",{"date":176,"type":41},"2025-03-16",{"date":178,"type":22},"2028-06-30",{"name":180,"class":48},"Shenzhen MagicRNA Biotechnology Co., Ltd",{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":17,"minAge":189,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":194,"conditions":195,"keywords":199,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":153},"100458576","clinico-biological-collection-to-investigate-the-physiopathology-of-systemic-autoimmune-diseases-100458576","NCT05251415","Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases","Constitution of a Collection of Biological Samples With the Aim of Carrying Out Clinico-biological and Pathophysiological Investigations of Systemic Autoimmune Diseases","ESSAi","Inclusion Criteria:\n\n* Patients with rare systemic autoimmune diseases (lupus, scleroderma, myositis for example),\n* Patients with atypical presentations of documented or probable systemic autoimmune diseases,\n* Patients receiving, or likely to receive new, innovative therapies (new molecule on the market, gene therapy, cell therapy, etc.).\n\nExclusion Criteria:\n\n* Known anemia and hemoglobin \\\u003C10 g \u002F dl\n* Patients under protective supervision (guardianship, curators)\n* Pregnant or breastfeeding woman","6 Years","99 Years",{"count":192,"type":22},3000,"OBSERVATIONAL","The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies",[196,32,66,197,198],"Lupus Erythematosus","Vasculitis","Inflammatory Bowel Diseases",[200,113,201,202,203,198,204],"systemic autoimmune diseases","lupus","myositis","vasculitis","new therapies","2026-03-16",{"date":207,"type":41},"2026-03-17",{"date":209,"type":41},"2022-04-04",{"date":211,"type":22},"2032-04-04",{"name":213,"class":152},"University Hospital, Toulouse",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":228,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":153},"100629092","clinical-study-of-evm18001-in-the-treatment-of-refractory-autoimmune-diseases-100629092","NCT07470151","Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases","Exploratory Clinical Study of EVM18001 Injection in the Treatment of Active Refractory Systemic Lupus Erythematosus, Myasthenia Gravis and Scleroderma","Inclusion Criteria:\n\n1. Voluntarily sign the Informed Consent Form (ICF), which must be signed by the participant or their legal guardian.\n2. At the time of signing the ICF, the age must be between 18 and 70 years (inclusive), regardless of gender.\n3. At screening, peripheral blood B cells must be CD19 positive, and T cells must express CD7.\n4. Confirmed autoimmune diseases based on recognized diagnostic criteria, including:\n\n   * SLE: Diagnosed with SLE according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) or 2019 European League Against Rheumatism (EULAR)\u002FACR criteria;\n   * MG: Diagnosed with MG according to the Myasthenia Gravis Foundation of America (MGFA) clinical classification;\n   * SSc: Diagnosed with SSc according to the 2013 ACR\u002FEULAR classification criteria.\n5. History of autoimmune disease for at least 6 months before screening and meets any of the following criteria. Definitions of active refractory SLE, active refractory SSc, and active refractory MG are as follows:\n\n   * Definition of active refractory SLE: SLEDAI-2000 score ≥6; and disease activity or relapse persists after at least 3 months of standard therapy (glucocorticoids combined with at least 2 immunosuppressants, or at least 1 imunosuppressant and 1 targeted therapy).\n   * Definition of active refractory SSc: Patients meeting the 2013 ACR\u002FEULAR classification criteria for SSc who still show disease activity or progression after at least 6 months of standard therapy (including steroids, immunosuppressants, vasodilators, or antifibrotic agents). Specific criteria include but are not limited to: mRSS increase ≥5 points or ≥25% from baseline; absolute value of predicted FVC% decrease ≥5%; DLCO% corrected for hemoglobin absolute value decrease ≥10%; new or worsening digital ulcers after ≥3 months of vasodilator therapy; persistent or recurrent organ involvement requiring intensified treatment.\n   * Definition of active refractory MG: Refers to generalized MG patients meeting MGFA diagnostic criteria with ongoing disease activity (MGFA II-IV, QMG ≥12, or MG-ADL ≥6), and includes at least one of the following: poor control after at least 12 months of standard therapy (including at least 2 immunosuppressants); need for ≥2 intravenous immunoglobulin (IVIG) or plasma exchange treatments in the past 12 months to control symptoms; relapse with prednisone ≥20 mg\u002Fday or reduction to \\\u003C10 mg\u002Fday; persistent or recurrent disease activity.\n6. Patients must meet the following conditions for concomitant medication:\n\n   1. Corticosteroids must have been used for more than 6 weeks prior to screening and at a stable dose of ≤ 10 mg\u002Fday prednisone or equivalent for at least 14 days prior to administration of EVM18001. Concurrent treatment with topical or inhaled corticosteroids (or other immunomodulators) is allowed;\n   2. Continued use during treatment is allowed if antimalarial drugs (eg, hydroxychloroquine, chloroquine, etc.) are started ≥ 12 weeks prior to screening and maintained at a stable dose for ≥ 8 weeks (maximum dose limit: hydroxychloroquine, 400 mg\u002Fday; chloroquine, 500 mg\u002Fday).\n7. Examination at screening meet any of the following criteria:\n\n   * SLE: positive for blood ANA, and\u002For positive for anti-dsDNA, anti-Smith antibodies;\n   * MG: Positive serology for anti-AChR antibodies or anti-musclespecific tyrosine kinase receptor (MuSK) antibodies.\n8. Life expectancy greater than 6 months.\n9. Bone marrow reserve and organ function are normal:\n\n   * Bone marrow function: defined as absolute neutrophil count (ANC) ≥ 1.0×109\u002FL, absolute lymphocyte count (ALC) ≥0.5×109\u002FL, hemoglobin (Hb) ≥80g\u002FL, platelet count (PLT) ≥50×109\u002FL. Blood transfusions and growth factors must not be used to meet these requirements within 7 days prior to screening for eligibility.\n   * Coagulation function: defined as international normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤ 1.5× upper limit of normal (ULN).\n   * Cardiac function: defined as left ventricular ejection fraction (LVEF) ≥ 45% as assessed by echocardiography (ECHO).\n   * Pulmonary function: defined as Common Terminology Criteria ≤for Adverse Events (CTCAE) Grade 1 dyspnea and oxygen saturation (SpO2) ≥ 92% (pulse oximetry) on room air.\n   * Hepatic function: defined as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN, total bilirubin \\\u003C 2.0mg\u002FdL (total bilirubin of Gilbert syndrome trial participants \\\u003C3.0mg\u002FdL).\n   * Renal function: defined as calculated creatinine clearance (Cockcroft-Gault) ≥ 50 mL\u002Fmin without hydration assistance.\n10. Female trial participants of childbearing potential:\n\n    * Negative serum β human chorionic gonadotropin (β-hCG) test at screening;\n    * Agree to use a highly effective method of contraception for the duration of study participation and for 12 months after EVM18001 last infusion.\n11. Male trial participant whose partner is of childbearing potential who agrees to use a highly effective method of contraception during the study and 12 months after the last infusion of the EVM18001.\n\nExclusion Criteria:\n\n1. Concurrent autoimmune diseases requiring systemic treatment.\n2. The autoimmune disease meets the following criteria:\n\n   * SLE: patients with renal crisis;\n   * MG: MGFA clinical classification type V or experiencing myasthenic crisis;\n   * SSc: involving lungs and exist severe ILD and severe PAH, or patients with scleroderma renal crisis.\n3. Any of the following conditions exist:\n\n   * Positive for Hepatitis B surface antigen (HBsAg)\u002Fcore antibody (HBcAb)\u002Fe-antibody (HBeAb)\u002Fe antigen (HBeAg);\n   * Positive for Hepatitis C virus (HCV) antibody;\n   * Positive for human immunodeficiency virus (HIV) antibody;\n   * Positive CMV DNA or above the upper limit of detection;\n   * Positive for syphilis antigen or antibody.\n4. Other uncontrolled active infections exist at screening.\n5. Creatinine clearance \\\u003C50 mL\u002Fmin.\n6. Estimated glomerular filtration rate \\\u003C45 mL\u002Fmin\u002F1.73m² (calculated using the MDRD creatinine equation from the Chronic Kidney Disease Epidemiology Collaboration; or serum creatinine \\>2.0 mg\u002FdL.\n7. History of major organ transplantation (such as heart, lung, liver, kidney) or bone marrow\u002Fhematopoietic stem cell transplantation.\n8. History within 6 months before screening of any of the following cardiovascular diseases: NYHA class III or IV heart failure, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmia, any ventricular arrhythmia, or other clinically significant heart disease.\n9. History of ≥grade 2 bleeding within 4 weeks before screening, or requiring long-term continuous anticoagulant therapy (such as warfarin, low molecular weight heparin, or factor Xa inhibitors, etc.).\n10. History within the past 24 weeks\u002F6 months of severe active central nervous system disease or pathology, including but not limited to: cerebrovascular accident, aneurysm, epilepsy, convulsions\u002Fseizures, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychiatric disorders. Stable patients will be assessed by the investigator for eligibility.\n11. Diagnosed with malignant tumors within the past 5 years. The following are excluded: non-melanoma skin cancer treated with radical therapy, localized prostate cancer, biopsy-confirmed cervical carcinoma in situ or squamous intraepithelial lesions detected by cervical smear, and completely resected breast carcinoma in situ.\n12. History of live vaccine administration within the past 4 weeks.\n13. Have received any of the following treatments:\n\n    * Preventive therapy with short-acting oral antiretroviral drugs within 7 days before first administration, or preventive therapy with longacting antiretroviral drugs within 2 years before first administration;\n    * Plasma exchange, plasmapheresis, or hemodialysis within 14 days before screening;\n    * Any other clinical study drug within 4 weeks before screening. However, if the study treatment was ineffective or the disease progressed, and at least 3 half-lives had passed before screening, enrollment is allowed;\n    * History of bone marrow transplantation, gene therapy, adoptive cell therapy, or any type of CAR-T cell therapy;\n    * Previously received any mRNA-LNP product or other LNP-based drugs.\n14. Unable to complete washout of previous treatment drugs as required within 4 weeks before first administration, or unable to maintain stable doses of concomitant medications for autoimmune diseases.\n15. Pregnant or breastfeeding women.\n16. Allergic to supportive medications required for managing CAR-T cell therapy toxicities (e.g., tocilizumab).\n17. Other situations where the investigator judges that the trial participant has poor compliance or is unwilling or unable to adhere to the study protocol.","70 Years",{"count":104,"type":22},[137],"A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the recommended dose for subsequent treatment. At the same time, the PK\u002FPD characteristics of EVM18001 will be evaluated, preliminary efficacy will be observed, and related biomarkers and immunogenicity will be explored.",[226,32,227],"System Lupus Erythematosus(SLE)","Myasthenia Gravis (MG)",[229,230,32,231,232,233],"Active Refractory Systemic Lupus Erythematosus","Myasthenia Gravis","EVM18001","CAR-T","Refractory Autoimmune Diseases","2026-03-10",{"date":236,"type":41},"2026-03-13",{"date":238,"type":22},"2026-03-12",{"date":240,"type":22},"2027-12",{"name":242,"class":152},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":131,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":249,"targetDuration":251,"studyType":193,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":153},"100393366","rheumatology-patient-registry-and-biorepository-100393366","NCT04402086","Rheumatology Patient Registry and Biorepository","Inclusion Criteria for Rheumatology Patients:\n\n* Patients ≥18 years old with a diagnosis of a rheumatic autoimmune disease including, but not limited to: adult onset Still's disease, ankylosing spondylitis, antiphospholipid syndrome, Behcet's disease, dermatomyositis, giant cell arteritis, mixed connective tissue disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease and vasculitis.\n* Receiving clinical care at Yale Rheumatology clinics\n\nExclusion Criteria for Rheumatology Patients:\n\n* Unable to provide informed consent\n* No patients will be excluded based on gender or ethnicity or pregnancy status.\n* Women who are currently pregnant will need to wait to donate a skin biopsy until after they deliver.\n* Patients allergic to lidocaine or epinephrine or have a history of impaired wound healing will not be able to donate a skin biopsy.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Age ≥ 18 years old\n* No chronic skin conditions\n* No diagnosis of a rheumatic autoimmune disease (e.g., lupus, rheumatoid arthritis)\n* Normal BMI\n\nExclusion Criteria for Healthy Volunteers:\n\n* Unable to provide informed consent.\n* Currently pregnant or nursing unless the study goal is to study pregnant or nursing woman.\n* Allergies to lidocaine or epinephrine (skin biopsies).\n* A history of impaired wound healing (skin biopsies).",{"count":250,"type":22},5000,"10 Years","To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.",[254,255,256,257,258,259,168,260,261,262,263,264,265,266,169,267,73,32,268,269],"Rheumatic Diseases","Adult Onset Still Disease","Ankylosing Spondylitis","Psoriatic Arthritis","Reactive Arthritis","Antiphospholipid Syndrome","Behcet Disease","Dermatomyositis","Polymyositis","Giant Cell Arteritis","Lyme Disease","Mixed Connective Tissue Disease","Polymyalgia Rheumatica","Sarcoidosis","Sjogren's Syndrome","Undifferentiated Connective Tissue Diseases","2026-02-11",{"date":272,"type":41},"2026-02-13",{"date":274,"type":41},"2020-08-04",{"date":276,"type":22},"2030-06-01",{"name":278,"class":152},"Yale University",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":288,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":305,"locationsCount":307},"100580894","phase-2-tibulizumab-systemic-sclerosis-understanding-and-response-evaluation-tibusure-100580894","NCT06843239","Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)","A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Systemic Sclerosis","Inclusion Criteria:\n\n* Male or female, 18 to 75 years of age\n* Body mass index between 18.0 and 38.0 kg\u002Fm²\n* Fulfills classification criteria for SSc according to ACR\u002FEULAR 2013 criteria\n* Has diffuse cutaneous SSc, defined as mRSS \\>0 over at least one skin area proximal to the elbows and\u002For knees, in addition to acral fibrosis\n* Has had SSc (defined as the first non-Raynaud's phenomenon (RP) symptom or sign attributed to SSc) for ≤7 years\n* mRSS ≥15 and ≤45 at screening. Additional requirements for participants ≥2 years to ≤7 years from SSc onset and RNA Polymerase III antibody positive\n* FVC \\>50% predicted\n* Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥40% predicted (corrected for hemoglobin)\n\nExclusion Criteria:\n\n* Has any of the following complications:\n\n  * Left ventricular failure\n  * Pulmonary arterial hypertension\n  * Renal crisis within previous 6 months\n  * Gastrointestinal dysmotility within previous 3 months\n  * Digital ischemia with gangrene, amputation, or unscheduled hospitalization within previous 3 months\n* Current rheumatic disease other than SSc that could interfere with assessment of SSc\n* Lung disease requiring continuous oxygen therapy\n* Evidence or suspicion of active or latent tuberculosis\n* Active Crohn's Disease or ulcerative colitis",{"count":287,"type":22},80,[26],"The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)",[30,32],[32,30,292,293,294,295,296,297,298],"Tibulizumab","Cutaneous","Interstitial lung disease (ILD)","Autoimmune diseases","Immune system diseases","Systemic Sclerosis interstitial lung disease (SSC-ILD)","Skin Diseases","2026-02-10",{"date":301,"type":41},"2026-02-12",{"date":303,"type":41},"2025-02-06",{"date":45,"type":22},{"name":306,"class":48},"Zura Bio Inc",51,{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":318,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":335},"100531075","phase-2-platform-clinical-study-for-conquering-scleroderma-100531075","NCT06195072","Platform Clinical Study for Conquering Scleroderma","Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants With Interstitial Lung Disease Secondary to Systemic Sclerosis","CONQUEST","Inclusion Criteria:\n\n1. Male or female 18+ years of age at the time of signed informed consent;\n2. SSc classification as defined by the 2013 American College of Rheumatology\u002FEuropean League Against Rheumatism criteria. Participants with diffuse, limited or sine cutaneous skin involvement are eligible\n3. Onset of SSc (defined by first non-Raynaud's symptom) 7 years or less prior to the Screening Visit;\n4. A Modified Rodnan skin score (mRSS) less than 40\n5. Presence of ILD with evidence of any fibrosis on HRCT (within 3 months or less of randomization)\n6. Presence of an FVC 45% or more predicted normal;\n7. Presence of a diffusing capacity of the lung for carbon monoxide (DLCO) 30% or more predicted normal, corrected for hemoglobin;\n\nOther protocol and\u002For subprotocol inclusion criteria apply.\n\nExclusion Criteria:\n\n1. Presence of clinically significant pulmonary abnormalities inconsistent with ILD on HRCT (e.g., scarring due to previous active tuberculosis \\[TB\\], sarcoidosis, lung mass, or other findings unrelated to SSc-ILD, as determined by a local radiologist\u002FInvestigator);\n2. Presence of infected ulcers or active gangrene at the Screening Visit;\n3. History of scleroderma renal crisis within 6 months prior to the Screening Visit;\n4. Forced expiratory volume in 1 second\u002FFVC \\\u003C0.65 (pre-bronchodilator) at the Screening Visit\n5. History of stem cell transplantation, bone marrow transplantation, chimeric antigen receptor T-cell therapy, or solid organ transplantation;\n6. History of treatment with rituximab within the 6 months prior to the Screening Visit;\n7. History treatment with cell-depleting therapies other than rituximab, including, but not limited to, CAMPATH®; anti-cluster of differentiation (CD)3, anti-CD4, anti-CD5, antiCD19, and anti-CD20 agents; and investigational agents\n8. Treatment with tocilizumab, nintedanib, pirfenidone, abatacept, leflunomide, tacrolimus, tofacitinib, intravenous immunoglobulin (IVIG), or any biologic or cyclophosphamide within 3 months prior to Screening Visit\n9. History of use of any investigational medication or device for any indication within 30 days or 5 half-lives (whichever is longer) prior to Screening Visit.\n10. Presence of any of the following laboratory findings at the Screening Visit:\n\n    * Estimated glomerular filtration rate \\\u003C45 mL\u002Fmin\u002F1.73 m2, calculated using the Chronic Kidney Disease Epidemiology Collaboration equation;\n    * Alanine aminotransferase or aspartate aminotransferase level \\> (2 x ULN);\n    * Platelets \\\u003C100 × 109\u002FL (100,000\u002FμL);\n    * White blood cell count \\\u003C2500\u002FμL;\n    * Neutrophil blood count \\\u003C1500\u002FμL;\n    * Prothrombin time and partial thromboplastin time \\>1.5 × ULN, or international normalized ratio \\>2; or\n    * Any other laboratory test result, that in the opinion of the Investigator, might place the study participant at risk for participation in the study.\n11. Presence of a clinically significant disorder that, in the opinion of the Investigator, could contraindicate the administration of study product, affect compliance, interfere with study evaluations, or confound the interpretation of study results\n12. Presence of a concomitant life-threatening disease with life expectancy \\\u003C12 months based on the Investigator's assessment;\n13. Evidence of active tuberculosis (TB) or being at high risk for TB\n\nOther protocol and\u002For subprotocol exclusion criteria apply.",{"count":317,"type":22},400,[26],"The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.",[321,32],"Interstitial Lung Disease Due to Systemic Disease",[323,113,324,112,35,325],"platform","interstitial lung disease","SSc-ILD","2026-02-02",{"date":328,"type":41},"2026-02-04",{"date":330,"type":41},"2024-04-15",{"date":332,"type":22},"2026-11",{"name":334,"class":152},"Scleroderma Research Foundation, Inc.",34,{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":131,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":153},"100612656","transcriptomic-study-of-cutaneous-fibroblasts-in-scleroderma-100612656","NCT07256418","Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma","TRANSCLERO","Inclusion Criteria:\n\nFOR PATIENTS WITH SCLERODERMA :\n\n* Person who has given written consent\n* Person with systemic scleroderma\n\nFOR CONTROL PARTICIPANTS :\n\n* Person who has given written consent\n* Person undergoing plastic, cosmetic and reconstructive surgery\n\nExclusion Criteria:\n\nFOR PATIENTS WITH SCLERODERMA :\n\n* Person not affiliated to or not benefiting from a social security scheme\n* Person subject to a legal protection measure (curatorship, guardianship)\n* Person subject to a legal protection measure\n* An adult who is incapable or unable to give consent\n* Minors\n\nFOR CONTROLLED PARTICIPANTS :\n\n* Person suffering from a chronic disease or under chronic treatment for autoimmune, inflammatory or dermatological diseases\n* Person not affiliated to or not benefiting from a social security scheme\n* Person under legal protection (curatorship, guardianship)\n* Person subject to a legal protection measure\n* An adult who is incapable or unable to give consent\n* Minors",{"count":344,"type":22},60,"Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senescent fibroblasts, which would be responsible for activating and\u002For maintaining the immune response and systemic inflammation. Our hypothesis is that fibroblasts play a predominant role in the genesis and maintenance of this pathology.",[32],"2026-01-28",{"date":349,"type":41},"2026-01-29",{"date":351,"type":41},"2026-01-26",{"date":353,"type":22},"2027-01",{"name":355,"class":152},"Centre Hospitalier Universitaire Dijon",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":131,"sex":363,"minAge":4,"maxAge":4,"enrollmentInfo":364,"targetDuration":366,"studyType":193,"phases":4,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":153},"100307028","maternal-autoimmune-disease-research-alliance-madra-registry-100307028","NCT03276923","Maternal Autoimmune Disease Research Alliance (MADRA) Registry","MADRA","Inclusion Criteria:\n\n* Desire for pregnancy within 6 months or currently pregnant\n* Women with systemic autoimmune disease, including:\n* Lupus (systemic lupus erythematosus or cutaneous lupus)\n* Antiphospholipid Syndrome or positive antiphospholipid antibodies\n* Rheumatoid Arthritis\n* Scleroderma (systemic sclerosis)\n* Sjogren's Syndrome\n* Inflammatory Arthritis (including Psoriatic Arthritis and Ankylosing Spondylitis)\n* Undifferentiated Connective Tissue Disease (UCTD)\n* Vasculitis\n* Myositis (Polymyositis or Dermatomyositis)\n* Positive Ro\u002FSSA or La\u002FSSB antibodies\n\nExclusion Criteria:\n\n* Unable to speak English\n* Unable to provide informed consent\n* Unable to travel to Duke University for follow-up visits","FEMALE",{"count":365,"type":22},1000,"100 Years","This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases.\n\nThe main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy.\n\nPrior studies demonstrate the importance of increase inflammation prior to and during pregnancy on these outcomes. The future research will seek to better define these risk factors and to identify ways to may improve them.",[369,370,168,371,169,268,32],"Autoimmune Diseases","Pregnancy Related","Cutaneous Lupus","2026-01-06",{"date":374,"type":41},"2026-01-08",{"date":376,"type":41},"2018-01-01",{"date":378,"type":22},"2027-01-01",{"name":380,"class":152},"Duke University",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":17,"minAge":388,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":392,"conditions":393,"keywords":399,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":153},"100615465","investigating-the-effectiveness-of-the-biopsychosocial-model-based-exercise-approach-in-children-and-adults-diagnosed-with-scleroderma-100615465","NCT07292961","Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma","Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach (BETY) in Children and Adults Diagnosed With Scleroderma: A Single-Blind Randomized Controlled Trial","\\*For a child diagnosed with scleroderma\\*\n\nInclusion Criteria:\n\n* Cases diagnosed with scleroderma,\n* Cases aged 7-18 years will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Cases that are not willing to participate in the study will be excluded.\n* History of developmental delay\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study\n\n\\*For adults diagnosed with scleroderma\\*\n\nInclusion Criteria:\n\n* Individuals diagnosed with scleroderma,\n* Individuals over the age of 18 will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Individuals who are not willing to participate in the study will be excluded.\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study","7 Years",{"count":390,"type":22},48,[137],"This study aims to investigate the effectiveness of BETY, an exercise approach based on the biopsychosocial model, in children and adults diagnosed with scleroderma.",[32,394,395,396,30,397,398],"Scleroderma, Localized","Scleroderma Systemic","Scleroderma (Limited and Diffuse)","Systemic Sclerosis - 2013 ACR\u002FEULAR Classification Criteria","Juvenile Systemic Sclerosis",[400,401,113,402],"biopsychosocial model","exercise","juvenile scleroderma","2025-12-06",{"date":405,"type":41},"2025-12-18",{"date":407,"type":41},"2025-12-04",{"date":409,"type":22},"2027-12-04",{"name":411,"class":152},"Hacettepe University",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":425,"overallStatus":430,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":4},"100544774","evaluating-tools-to-communicate-scleroderma-research-results-to-patients---trial-1-100544774","NCT06373263","Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1","A Randomized Controlled Trial to Compare the Effectiveness of Dissemination Tools to Share Research Results With Patients - SPIN-CLEAR Trial #1","SPIN-CLEAR #1","Inclusion Criteria:\n\n1. Enrollment in SPIN Cohort, which requires a systemic sclerosis (SSc) classification by a site physician based on 2013 American College of Rheumatology\u002FEuropean League Against Rheumatism criteria, ≥18 years old, being fluent in English or French, and have completed one SPIN Cohort assessment in the last year.\n2. External enrollment with patient-reported physician classification of SSc and age 18 or older.\n\nExclusion Criteria:\n\nPatients not able to access or respond to questionnaires via the internet are excluded.",{"count":421,"type":22},128,[137],"Sharing research results with patients is required by ethical regulations. Yet, most researchers do not share results from their studies with patients. The investigators plan to conduct a series of randomized controlled trials among people with scleroderma, a rare autoimmune disease, in a large international cohort, to identify the most effective methods for communicating study results with patients.\n\nThe first trial in the series will compare a research dissemination tool (infographic) against a plain-language summary comparator. Participants will be randomly assigned to receive the dissemination tool or comparator. Study participants will rate communication tools for (1) information completeness; (2) understandability; and (3) ease of use of format. Our results can be used by researchers and patient organizations who disseminate research results so that they can tailor the way they disseminate results to patient needs.",[32,73],[32,426,427,428,429,73],"Knowledge Translation","Dissemination Tools","E-Health","Intervention","NOT_YET_RECRUITING","2025-12-01",{"date":433,"type":41},"2025-12-08",{"date":435,"type":22},"2025-12-05",{"date":437,"type":22},"2026-01-02",{"name":439,"class":152},"Lady Davis Institute",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":448,"conditions":449,"keywords":456,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":466,"locationsCount":104},"100561258","a-biospecimen-collection-study-to-identify-the-targets-of-disease-reactive-t-cells-in-patients-with-autoimmune-disease-100561258","NCT06587828","A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease","Cohort Legend: Cohort 1: Inflammatory Bowel Diseases - Crohn's Disease or Ulcerative Colitis, Cohort 2: Celiac Disease, Cohort 3: Ankylosing spondylitis or non-radiographic axial spondyloarthritis (nr-axSpA), Cohort 4: Multiple Sclerosis, Cohort 5: Scleroderma, Cohort 6: Systemic Sclerosis with pulmonary involvement, Cohort 7: Other Autoimmune Disease, Cohort 8: Apparent Evolving Autoimmune Disease, Cohort 9: Frozen Cryopreserved\n\nInclusion Criteria:\n\n* Study cohorts 1,2,3,4,5,6,7,8.9: Known or suspected diagnosis, with subsequent diagnostic confirmation, of one of the following cohorts associated with the following autoimmune diseases:\n* Inflammatory Bowel Diseases - Crohn's Disease or ulcerative colitis\n* Celiac disease\n* Ankylosing spondylitis or Non radiographic axial spondyloarthritis (nr-axSpA)\n* Multiple sclerosis\n* Scleroderma\n* Systemic sclerosis with pulmonary involvement\n* Other autoimmune disease (as agreed between Investigator and Sponsor)\n* Apparent evolving autoimmune disease\n* Frozen cryopreserved\n* Age equal or greater than 18 years at time of informed consent.\n* Ability to understand and willingness to sign an informed consent document when informed consent is required by an ethical review board.\n* On disease-modifying treatments that are not known to be directly T cell toxic.\n\nSuch treatments are allowed and include:\n\n* Non-steroidal anti-inflammatory drugs including aspirin, ibuprofen, acetaminophen, celecoxib, indomethacin, diclofenac, etodolac, naproxen, meloxicam, sulindac, nabumetone amongst others.\n* Tumor necrosis factor alpha (TNF-alpha) antagonists including infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and biosimilar drugs with the same generic name.\n* Interleukin-12\u002F23 antagonists including ustekinumab (Stelara) and risankizumab-rzaa (Skyrizi)\n* Alpha-4-integrin antagonists including vedolizumab (Entyvio), natalizumab (Tysabri)\n* Interleukin-17 inhibitors including secukinumab (Cosentyx), ixekizumab (Taltz)\n* Recombinant interferon beta\n* CD20 antagonists including rituximab (Rituxan), ocrelizumab (Ocrevus), ofatumumab (Kesimpta)\n* Oral fumarates including dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), monomethyl fumarate (Bafiertam)\n* Oral sphingosine 1-phosphate receptor (S1PR) modulators including fingolimod (Gilenya), siponimod (Mayzent), ozanimod (Zeposia), ponesimod (Ponvory)\n* Oral glatiramer acetate (copolymer 1; Copaxone)\n* Patient is an appropriate candidate for a procedure to obtain a biopsy, tissue samples or biologic materials during a clinically indicated procedure where it is expected that excess materials could be used for research OR\n* In the opinion of the clinical investigator, a patient is an appropriate, low-risk candidate for a research only procedure to obtain a biopsy, tissue samples or biologic materials.\n\nExclusion Criteria:\n\n* On treatment with drugs that are known to be T cell toxic and cannot be held for at least 4 weeks or longer. The following treatments are not allowed except in designated cohorts when approved by Sponsor:\n* Glucocorticoids including prednisone, methylprednisolone (Solu-medrol), budesonide (Entocort), hydrocortisone (Solu-cortef), dexamethasone (Decadron), betamethasone (Betaject)\n* Sulfasalazine (Azulfidine)\n* Aminosalicylates including mesalamine\u002F mesalazine (Asacol, Pentasa).\n* Thiopurines including azathioprine (Imuran) and 6-mercaptopurine (Purixan)\n* Systemic JAK inhibitors including tofacitinib (Xeljanz), abrocitinib (Cibinqo), baricitinib (Olumiant), upadacitinib (Rinvoq)\n* CD52 inhibitors including alemtuzumab (Campath)\n* Methotrexate\n* Cladribine\n* Teriflunomide (Aubagio)\n* Concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical or psychiatric disorder that would interfere with the subject's safety.\n* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n* Patients receiving research biopsy procedures will not have a history of serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine), if local anesthetic is required for the procedure or to medications used for sedation during a procedure.\n* Pregnant or nursing women are excluded because there may be unanticipated adverse events and increased risk to both mother and fetus in the setting of local anesthetic or study procedures.\n* Any other medical or psychiatric condition, which in the opinion of the patient's treating clinician, would make participation in this protocol unreasonably hazardous for the patient.",{"count":447,"type":22},300,"The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation. These tissues contain both cytotoxic and helper T cells that are driving their disease, and these T cells are being guided by TCRs that recognize tissue-specific targets. By collecting tissue when a patient has active inflammation, it is possible to determine which T cells are activated and undergoing clonal expansion in the patient's diseased organ. TScan has developed a genome-wide, high-throughput technology to determine the natural, physiological target of any TCR (Kula, 2019). The goal of this study is to isolate T cells from inflamed tissues and matched blood samples and\u002For matched normal tissues (for patients with inflammatory bowel diseases). T cell clones that are expanded in diseased tissues relative to blood or normal tissues will be selected and the targets of their TCRs will be defined using TScan's genome-wide, high-throughput target ID technology.\n\nThe goal of this study is to discover a collection of peptide targets, along with their associated TCRs to be developed as new tolerogenic therapies for patients with autoimmune diseases.",[369,450,451,32,256,452,453,454,455],"Ulcerative Colitis","Multiple Sclerosis","Celiac Disease","Non-radiographic Axial Spondyloarthritis (Nr-axSpA)","Crohn&Amp;#39;s Disease","Birdshot Chorioretinitis",[369,451,73,256,32,457,458,459,455],"Inflammatory Bowel Disease","Crohn's Disease","Non-radiographic axial spondyloarthritis (nr-axSpA)","2025-11-21",{"date":462,"type":41},"2025-11-24",{"date":464,"type":41},"2023-01-03",{"date":353,"type":22},{"name":467,"class":48},"TScan Therapeutics, Inc.",{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":131,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":476,"conditions":477,"keywords":478,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":153},"100182926","scleroderma-registry--repository-at-the-hospital-for-special-surgery-100182926","NCT01656447","Scleroderma Registry & Repository at the Hospital for Special Surgery","The Scleroderma Registry & Repository","Inclusion Criteria:\n\n* Individuals older than 18 years of age with Scleroderma\n\nExclusion Criteria:\n\n* Individuals younger than 18 years of age\n* Individuals older than 18 years of age without Scleroderma",{"count":447,"type":22},"The overall objective of the Scleroderma Registry is to support and promote the basic science and clinical research of this complex rheumatic disease at the Hospital for Special Surgery (HSS). The registry facilitates our understanding of the clinical features, pathobiology, genetics of Scleroderma. This will ultimately lead to a potential treatment for this currently untreatable condition.",[32],[32,479,480],"Scleroderma Registry","Hospital for Special Surgery Scleroderma","2025-11-19",{"date":483,"type":41},"2025-11-26",{"date":485,"type":4},"2006-08",{"date":487,"type":22},"2030-01",{"name":489,"class":152},"Hospital for Special Surgery, New York",{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":498,"briefSummary":499,"conditions":500,"keywords":502,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":513},"100423700","phase-2-sildenafil-for-early-pulmonary-vascular-disease-in-scleroderma-100423700","NCT04797286","Sildenafil for Early Pulmonary Vascular Disease in Scleroderma","SEPVADIS","Inclusion Criteria:\n\n* Previous documentation of mean pulmonary artery pressure between 21 and 24 mm Hg with a pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) ≤ 15 mm Hg within six months before study entry.\n* Diagnosis of SSc according to 2013 American College of Rheumatology\u002F European League Against Rheumatism (ACR\u002FEULAR) classification criteria.\n* Pulmonary function tests with forced expiratory volume in one second\u002Fforced vital capacity (FEV1\u002FFVC) \\>50% AND either a) total lung capacity (TLC) or forced vital capacity (FVC) \\> 70% predicted or b) TLC or FVC between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest on studies obtained within 6 months of enrollment.\n* Ventilation perfusion scan or computed tomography with intravenous contrast (CT angiogram) without evidence of chronic thromboembolism at anytime before study entry.\n* Ability to perform six minute walk testing without significant limitations in musculoskeletal function or coordination.\n* Informed consent.\n\nExclusion Criteria:\n\n* World Health Organization (WHO) Class IV functional status.\n* Systolic blood pressure less than 90 mmHg at screening visit prior to enrollment.\n* Clinically significant untreated sleep apnea.\n* Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction \\\u003C 45% on most recent echocardiography (within 1 year).\n* Use of Pulmonary Arterial Hypertension (PAH) therapy (prostacyclin analogues, endothelin-1 receptor antagonists,phosphodiesterase-5 inhibitors, riociguat, selexipag) within the past 3 months.\n* Hospitalized or acutely ill.\n* Renal failure (creatinine above 2.0) at screening visit.\n* Enrollment in a clinical trial or concurrent use of another investigational drug (non FDA approved) or device therapy within 30 days of screening visit.\n* Age \\\u003C 18.\n* Currently pregnant.\n* Current use of nitrates.",{"count":164,"type":22},[26],"This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.",[32,501],"Mildly Elevated Pulmonary Pressures",[503],"SSc-MEP","2025-10-13",{"date":506,"type":41},"2025-10-15",{"date":508,"type":41},"2021-09-20",{"date":510,"type":22},"2026-09-01",{"name":512,"class":152},"Johns Hopkins University",2,{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":388,"maxAge":4,"enrollmentInfo":521,"targetDuration":523,"studyType":193,"phases":4,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":153},"100607016","patients-diagnosed-with-scleroderma-physical-performance-and-functionality-100607016","NCT07183072","Patients Diagnosed With Scleroderma: Physical Performance and Functionality","Investigating the Relationship Between the Biopsychosocial Status of Individuals Diagnosed With Scleroderma and Their Physical Performance and Functionality","\\*For a child diagnosed with scleroderma\\*\n\nInclusion Criteria:\n\n* Cases diagnosed with scleroderma,\n* Cases aged 7-18 years will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Cases that are not willing to participate in the study will be excluded.\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study\n\n\\*For adults diagnosed with scleroderma\\*\n\nInclusion Criteria:\n\n* Individuals diagnosed with scleroderma,\n* Individuals over the age of 18 will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Individuals who are not willing to participate in the study will be excluded.\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study",{"count":522,"type":22},50,"2 Weeks","Physical functionality and performance are important for individuals diagnosed with scleroderma. There is a need to address children and adults diagnosed with scleroderma comprehensively and to evaluate them on a biopsychosocial basis to support their disease management. In light of all this literature, the aim was to evaluate the biopsychosocial characteristics of both pediatric and adult scleroderma patients and to examine their physical performance and functionality.\n\nAdditionally, this study aims to identify effective tests that can be used in future research to assess physical performance and functionality in individuals diagnosed with scleroderma.",[30,32,396,394,526],"Functionality",[528,113,112,529,530],"Juvenile scleroderma","physical performance","functionality","2025-09-13",{"date":533,"type":41},"2025-09-19",{"date":535,"type":41},"2025-08-04",{"date":537,"type":22},"2027-08-04",{"name":411,"class":152},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":388,"maxAge":4,"enrollmentInfo":546,"targetDuration":523,"studyType":193,"phases":4,"briefSummary":547,"conditions":548,"keywords":550,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":553,"leadSponsor":554,"locationsCount":153},"100607009","patients-diagnosed-with-scleroderma-and-their-chewing-and-swallowing-performance-100607009","NCT07182981","Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance","Investigating the Relationship Between the Biopsychosocial Status of Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance","For a child diagnosed with scleroderma:\n\nInclusion Criteria:\n\n* Cases diagnosed with scleroderma,\n* Cases aged 7-18 years will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Cases that are not willing to participate in the study will be excluded.\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study\n\nFor adults diagnosed with scleroderma:\n\nInclusion Criteria:\n\n* Individuals diagnosed with scleroderma,\n* Individuals over the age of 18 will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Individuals who are not willing to participate in the study will be excluded.\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study",{"count":522,"type":22},"It is recommended to focus on the physical functionality, chewing, and swallowing performance of individuals diagnosed with scleroderma. There is a need to address children and adults diagnosed with scleroderma comprehensively and to evaluate them on a biopsychosocial basis to support their disease management. The aim was to assess the biopsychosocial characteristics of both children and adults diagnosed with scleroderma and to examine their chewing and swallowing performance.\n\nAdditionally, this study aims to identify effective scales that can be used in future research to assess chewing and swallowing in individuals diagnosed with scleroderma.",[30,32,396,394,549],"Swallowing",[528,113,112],{"date":533,"type":41},{"date":535,"type":41},{"date":537,"type":22},{"name":411,"class":152},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":568,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":153},"100382862","cohort-of-patients-with-systemic-sclerosis-within-the-framework-of-the-reso-reference-centre-100382862","NCT04265144","Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre","Cohort of Patients With Systemic Sclerosis and Associated Biological Collection Within the Framework of the RESO Reference Centre for Rare Systemic Autoimmune Diseases","SCLERESO","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient with systemic scleroderma according to the ACR\u002FEULAR 2013 criteria, or with a \" very early systemic sclerosis \" defined by the presence of Raynaud's phenomenon and auto-antibodies in blood sample (ACAN positivity (≥1\u002F160) with anti-Scl70, anti-centromere or anti-ARNPolIII specificity).\n* Person affiliated or benefiting from a social security scheme.\n* Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research)\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Patient under guardianship, curatorship or any other legal protection regime",{"count":564,"type":22},500,[137],"Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by vascular involvement and the intensity of fibrosis. The lack of available treatment is largely due to the very fragmented understanding of the pathophysiology of SSc. However, one of the keys to conducting quality research on this disease remains the development of well-documented patient cohorts with reliable biological samples. The main objective of this cohort is to study the natural progression of SSc in a cohort of patients followed over 5 years.",[32,73],[569,112,570],"Cohort study","prognosis","2025-09-03",{"date":573,"type":41},"2025-09-04",{"date":575,"type":41},"2020-06-08",{"date":577,"type":22},"2034-06",{"name":579,"class":152},"University Hospital, Bordeaux",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":588,"enrollmentInfo":589,"targetDuration":4,"studyType":23,"phases":590,"briefSummary":592,"conditions":593,"keywords":594,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":123},"100446843","phase-2-preventive-effect-of-clopidogrel-on-the-systemic-sclerosis-development-risk-100446843","NCT05098704","Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk","Phase II\u002FIII Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon","PSSIT","Inclusion Criteria:\n\n* Patient over 18 years old, and less than 85 years old.\n* Patient with positive AAN (AAN ≥ 1\u002F160) with the following specificity: anti-Scl70 or anti-centromere or anti-RNApolIII, or any other auto-antibodies related to systemic sclerosis\n* Patient with RP reported by the subject and confirmed by the physician.\n* Patient affiliated to a health insurance system.\n* Patient who accepts to participate to the study and signs an inform consent form.\n\nExclusion Criteria:\n\n* Patient with an SSc diagnosis according to ACR\u002FEULAR 2013 criteria.\n* Patient with skin fibrosis at screening.\n* Patient with antiplatelet treatment at screening.\n* Patient with contraindications to clopidogrel.\n* Patient treated by immunosuppressive agent at screening.\n* Patient treated by anticoagulants at screening\n* Pregnant or breastfeeding women.\n* Women of childbearing age refusing effective contraception method during the study treatment (24 months).\n* Incompetent adults (i.e. Individuals under the protection of a conservator)","85 Years",{"count":58,"type":22},[26,591],"PHASE3","Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies. The association of Raynaud phenomenon and SSc-specific anti-nuclear antibodies is the hallmark of pre-scleroderma subjects, among who around 47% declare a complete disease after five years. The aim of this study is to assess in this particular population the preventive effect of an anti-platelet treatment.",[32,73],[112,595,596,597,598],"clopidogrel","platelet","prevention","primary care","2025-07-11",{"date":601,"type":41},"2025-07-14",{"date":603,"type":41},"2022-06-22",{"date":605,"type":22},"2031-06",{"name":579,"class":152},{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":616,"briefSummary":617,"conditions":618,"keywords":620,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":153},"100565802","phase-1-tens-in-scleroderma-100565802","NCT06646913","TENS in Scleroderma","Transcutaneous Electrical Nerve Stimulation in Scleroderma","Inclusion Criteria:\n\n1. Classification of Systemic Sclerosis according to the 2013 American College of Rheumatology and European League against Rheumatism classification criteria.\n2. Age \\>= 18 years\n3. English speaking.\n4. Participants who report moderate to severe symptoms of distension\u002Fbloating on UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0\n5. Stable GI specific therapy including prokinetics over the last 4 weeks.\n\nExclusion Criteria:\n\n1. Pregnancy, or currently lactating.\n2. A history of major abdominal surgery (other than cholecystectomy, appendectomy, or deemed as non-major by the investigators)\n3. Unrelated active disorder which may involve abdominal pain, such as inflammatory bowel disease, diabetes or unstable thyroid disease.\n4. Known allergy to adhesive ECG electrodes.\n5. Known contraindications to TEA (e.g., cardiac pacemaker, epilepsy)",{"count":615,"type":22},16,[25],"The goal of this pilot study is to assess the acceptability of the transcutaneous electrical acustimulation (TEA) device in treating Scleroderma-related gastroparesis. The main objective is:\n\nTo evaluate the acceptability of TEA as an intervention for alleviating symptoms of distension and bloating in individuals diagnosed with Scleroderma.\n\nParticipants will be provided with the TEA devices that will be applied to the skin for a total of 45 minutes twice daily after meals. Participants will be asked to fill out both daily diaries and biweekly questionnaires to assess for improvement in the gastroparesis symptoms. Participants will also be asked to complete the daily diaries in addition weekly questionnaires during a 4 week post-treatment follow-up period.",[32,619,30],"Gastroparesis",[621,32,619,622,73],"TENS","Pilot Study","2025-06-30",{"date":625,"type":41},"2025-07-03",{"date":627,"type":41},"2024-10-01",{"date":629,"type":22},"2026-05",{"name":631,"class":152},"University of Michigan",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":640,"targetDuration":366,"studyType":193,"phases":4,"briefSummary":642,"conditions":643,"keywords":984,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":1027,"lastUpdatePostDateStruct":1028,"startDateStruct":1030,"completionDateStruct":1032,"leadSponsor":1034,"locationsCount":513},"100193378","rare-disease-patient-registry--natural-history-study---coordination-of-rare-diseases-at-sanford-100193378","NCT01793168","Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford","Coordination of Rare Diseases at Sanford","CoRDS","Inclusion Criteria:\n\n* Diagnosis of a rare disease, a disease of unknown prevalence, undiagnosed or an unaffected carrier of a rare\u002Funcommon disease\n\nExclusion Criteria:\n\n* Diagnosis of a disease which is not rare",{"count":641,"type":22},20000,"CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access. Visit sanfordresearch.org\u002FCoRDS to enroll.",[644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,264,230,675,676,677,678,679,680,681,682,683,684,685,686,687,688,689,690,691,692,693,694,695,696,697,698,699,700,701,702,703,704,705,706,707,708,709,710,711,712,713,714,715,716,717,718,719,720,721,722,723,724,725,726,727,728,729,730,731,732,733,734,735,736,737,738,739,740,741,742,743,744,745,746,747,748,749,750,751,752,753,754,755,756,757,758,759,760,761,762,763,764,765,766,767,768,769,770,771,772,773,774,775,776,777,778,779,780,781,782,783,784,785,786,787,788,789,790,791,792,793,794,795,796,797,798,799,800,801,802,803,804,805,806,807,808,809,810,811,812,813,814,815,816,817,818,819,820,821,822,823,824,825,826,827,828,829,830,831,832,833,834,835,836,837,838,839,840,841,842,843,844,845,846,847,848,849,850,851,852,853,854,855,856,857,858,859,860,861,862,863,864,865,866,867,868,869,870,871,872,873,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,891,892,893,894,895,896,897,898,899,900,901,902,903,904,905,906,907,908,909,910,911,912,913,914,915,916,917,918,919,920,921,922,923,924,925,926,927,928,929,930,32,931,932,933,934,935,936,937,938,939,940,941,942,943,944,945,946,947,948,949,950,951,952,953,954,955,956,957,958,959,960,961,962,963,964,965,966,967,968,969,970,971,972,973,974,975,976,977,978,979,980,981,982,983],"Rare Disorders","Undiagnosed Disorders","Disorders of Unknown Prevalence","Cornelia De Lange Syndrome","Prenatal Benign Hypophosphatasia","Perinatal Lethal Hypophosphatasia","Odontohypophosphatasia","Adult Hypophosphatasia","Childhood-onset Hypophosphatasia","Infantile Hypophosphatasia","Hypophosphatasia","Kabuki Syndrome","Bohring-Opitz Syndrome","Narcolepsy Without Cataplexy","Narcolepsy-cataplexy","Hypersomnolence Disorder","Idiopathic Hypersomnia Without Long Sleep Time","Idiopathic Hypersomnia With Long Sleep Time","Idiopathic Hypersomnia","Kleine-Levin Syndrome","Kawasaki Disease","Leiomyosarcoma","Leiomyosarcoma of the Corpus Uteri","Leiomyosarcoma of the Cervix Uteri","Leiomyosarcoma of Small Intestine","Acquired Myasthenia Gravis","Addison Disease","Hyperacusis (Hyperacousis)","Juvenile Myasthenia Gravis","Transient Neonatal Myasthenia Gravis","Williams Syndrome","Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome)","Isolated Klippel-Feil Syndrome","Frasier Syndrome","Denys-Drash Syndrome","Beckwith-Wiedemann Syndrome","Emanuel Syndrome","Isolated Aniridia","Axenfeld-Rieger Syndrome","Aniridia-intellectual Disability Syndrome","Aniridia - Renal Agenesis - Psychomotor Retardation","Aniridia - Ptosis - Intellectual Disability - Familial Obesity","Aniridia - Cerebellar Ataxia - Intellectual Disability","Aniridia - Absent Patella","Aniridia","Peters Anomaly - Cataract","Peters Anomaly","Potocki-Shaffer Syndrome","Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11","Silver-Russell Syndrome Due to Imprinting Defect of 11p15","Silver-Russell Syndrome Due to 11p15 Microduplication","Syndromic Aniridia","WAGR Syndrome","Wolf-Hirschhorn Syndrome","4p16.3 Microduplication Syndrome","4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome","Autosomal Recessive Stickler Syndrome","Stickler Syndrome Type 2","Stickler Syndrome Type 1","Stickler Syndrome","Mucolipidosis Type 4","X-linked Spinocerebellar Ataxia Type 4","X-linked Spinocerebellar Ataxia Type 3","X-linked Intellectual Disability - Ataxia - Apraxia","X-linked Progressive Cerebellar Ataxia","X-linked Non Progressive Cerebellar Ataxia","X-linked Cerebellar Ataxia","Vitamin B12 Deficiency Ataxia","Toxic Exposure Ataxia","Unclassified Autosomal Dominant Spinocerebellar Ataxia","Thyroid Antibody Ataxia","Sporadic Adult-onset Ataxia of Unknown Etiology","Spinocerebellar Ataxia With Oculomotor Anomaly","Spinocerebellar Ataxia With Epilepsy","Spinocerebellar Ataxia With Axonal Neuropathy Type 2","Spinocerebellar Ataxia Type 8","Spinocerebellar Ataxia Type 7","Spinocerebellar Ataxia Type 6","Spinocerebellar Ataxia Type 5","Spinocerebellar Ataxia Type 4","Spinocerebellar Ataxia Type 37","Spinocerebellar Ataxia Type 36","Spinocerebellar Ataxia Type 35","Spinocerebellar Ataxia Type 34","Spinocerebellar Ataxia Type 32","Spinocerebellar Ataxia Type 31","Spinocerebellar Ataxia Type 30","Spinocerebellar Ataxia Type 3","Spinocerebellar Ataxia Type 29","Spinocerebellar Ataxia Type 28","Spinocerebellar Ataxia Type 27","Spinocerebellar Ataxia Type 26","Spinocerebellar Ataxia Type 25","Spinocerebellar Ataxia Type 23","Spinocerebellar Ataxia Type 22","Spinocerebellar Ataxia Type 21","Spinocerebellar Ataxia Type 20","Spinocerebellar Ataxia Type 2","Spinocerebellar Ataxia Type 19\u002F22","Spinocerebellar Ataxia Type 18","Spinocerebellar Ataxia Type 17","Spinocerebellar Ataxia Type 16","Spinocerebellar Ataxia Type 15\u002F16","Spinocerebellar Ataxia Type 14","Spinocerebellar Ataxia Type 13","Spinocerebellar Ataxia Type 12","Spinocerebellar Ataxia Type 11","Spinocerebellar Ataxia Type 10","Spinocerebellar Ataxia Type 1 With Axonal Neuropathy","Spinocerebellar Ataxia Type 1","Spinocerebellar Ataxia - Unknown","Spinocerebellar Ataxia - Dysmorphism","Non Progressive Epilepsy and\u002For Ataxia With Myoclonus as a Major Feature","Spasticity-ataxia-gait Anomalies Syndrome","Spastic Ataxia With Congenital Miosis","Spastic Ataxia - Corneal Dystrophy","Spastic Ataxia","Rare Hereditary Ataxia","Rare Ataxia","Recessive Mitochondrial Ataxia Syndrome","Progressive Epilepsy and\u002For Ataxia With Myoclonus as a Major Feature","Posterior Column Ataxia - Retinitis Pigmentosa","Post-Stroke Ataxia","Post-Head Injury Ataxia","Post Vaccination Ataxia","Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract","Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus","Non-hereditary Degenerative Ataxia","Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity","Olivopontocerebellar Atrophy - Deafness","NARP Syndrome","Myoclonus - Cerebellar Ataxia - Deafness","Multiple System Atrophy, Parkinsonian Type","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy","Maternally-inherited Leigh Syndrome","Machado-Joseph Disease Type 3","Machado-Joseph Disease Type 2","Machado-Joseph Disease Type 1","Leigh Syndrome","Late-onset Ataxia With Dementia","Infection or Post Infection Ataxia","GAD Ataxia","Hereditary Episodic Ataxia","Gliadin\u002FGluten Ataxia","Friedreich Ataxia","Fragile X-associated Tremor\u002FAtaxia Syndrome","Familial Paroxysmal Ataxia","Exposure to Medications Ataxia","Episodic Ataxia With Slurred Speech","Episodic Ataxia Unknown Type","Episodic Ataxia Type 7","Episodic Ataxia Type 6","Episodic Ataxia Type 5","Episodic Ataxia Type 4","Episodic Ataxia Type 3","Episodic Ataxia Type 1","Epilepsy and\u002For Ataxia With Myoclonus as Major Feature","Early-onset Spastic Ataxia-neuropathy Syndrome","Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity","Early-onset Cerebellar Ataxia With Retained Tendon Reflexes","Early-onset Ataxia With Dementia","Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia","Dilated Cardiomyopathy With Ataxia","Cataract - Ataxia - Deafness","Cerebellar Ataxia, Cayman Type","Cerebellar Ataxia With Peripheral Neuropathy","Cerebellar Ataxia - Hypogonadism","Cerebellar Ataxia - Ectodermal Dysplasia","Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss","Brain Tumor Ataxia","Brachydactyly - Nystagmus - Cerebellar Ataxia","Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia","Autosomal Recessive Syndromic Cerebellar Ataxia","Autosomal Recessive Spastic Ataxia With Leukoencephalopathy","Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay","Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria","Autosomal Recessive Spastic Ataxia","Autosomal Recessive Metabolic Cerebellar Ataxia","Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine","Autosomal Recessive Ataxia, Beauce Type","Autosomal Recessive Ataxia Due to Ubiquinone Deficiency","Autosomal Recessive Ataxia Due to PEX10 Deficiency","Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia","Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency","Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency","Autosomal Recessive Congenital Cerebellar Ataxia","Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome","Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity","Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency","Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect","Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion","Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation","Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness","Autosomal Recessive Cerebellar Ataxia","Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly","Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation","Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy","Autosomal Dominant Spastic Ataxia Type 1","Autosomal Dominant Spastic Ataxia","Autosomal Dominant Optic Atrophy","Ataxia-telangiectasia Variant","Ataxia-telangiectasia","Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy","Autosomal Dominant Cerebellar Ataxia Type 4","Autosomal Dominant Cerebellar Ataxia Type 3","Autosomal Dominant Cerebellar Ataxia Type 2","Autosomal Dominant Cerebellar Ataxia Type 1","Autosomal Dominant Cerebellar Ataxia","Ataxia-telangiectasia-like Disorder","Ataxia With Vitamin E Deficiency","Ataxia With Dementia","Ataxia - Oculomotor Apraxia Type 1","Ataxia - Other","Ataxia - Genetic Diagnosis - Unknown","Acquired Ataxia","Adult-onset Autosomal Recessive Cerebellar Ataxia","Alcohol Related Ataxia","Multiple Endocrine Neoplasia","Multiple Endocrine Neoplasia Type II","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Multiple Endocrine Neoplasia, Type IV","Multiple Endocrine Neoplasia, Type 3","Multiple Endocrine Neoplasia (MEN) Syndrome","Multiple Endocrine Neoplasia Type 2B","Multiple Endocrine Neoplasia Type 2A","Atypical Hemolytic Uremic Syndrome","Atypical HUS","Wiedemann-Steiner Syndrome","Breast Implant-Associated Anaplastic Large Cell Lymphoma","Autoimmune\u002FInflammatory Syndrome Induced by Adjuvants (ASIA)","Hemophagocytic Lymphohistiocytosis","Behcet's Disease","Alagille Syndrome","Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)","Lowe Syndrome","Pitt Hopkins Syndrome","1p36 Deletion Syndrome","Jansen Type Metaphyseal Chondrodysplasia","Cockayne Syndrome","Chronic Recurrent Multifocal Osteomyelitis","CRMO","Malan Syndrome","Hereditary Sensory and Autonomic Neuropathy Type Ie","VCP Disease","Hypnic Jerking","Sleep Myoclonus","Mollaret Meningitis","Recurrent Viral Meningitis","CRB1","Leber Congenital Amaurosis","Retinitis Pigmentosa","Rare Retinal Disorder","KCNMA1-Channelopathy","Primary Biliary Cirrhosis","ZMYND11","Transient Global Amnesia","Glycogen Storage Disease","Alstrom Syndrome","White Sutton Syndrome","DNM1","EIEE31","Myhre Syndrome","Recurrent Respiratory Papillomatosis","Laryngeal Papillomatosis","Tracheal Papillomatosis","Refsum Disease","Nicolaides Baraitser Syndrome","Leukodystrophy","Tango2","Cauda Equina Syndrome","Rare Gastrointestinal Disorders","Achalasia-Addisonian Syndrome","Achalasia Cardia","Achalasia Icrocephaly Syndrome","Anal Fistula","Congenital Sucrase-Isomaltase Deficiency","Eosinophilic Gastroenteritis","Idiopathic Gastroparesis","Hirschsprung Disease","Rare Inflammatory Bowel Disease","Intestinal Pseudo-Obstruction","Short Bowel Syndrome","Sacral Agenesis","Sacral Agenesis Syndrome","Caudal Regression","Scheuermann Disease","SMC1A Truncated Mutations (Causing Loss of Gene Function)","Cystinosis","Juvenile Nephropathic Cystinosis","Nephropathic Cystinosis","Kennedy Disease","Spinal Bulbar Muscular Atrophy","Warburg Micro Syndrome","Mucolipidoses","Mitochondrial Diseases","Mitochondrial Aminoacyl-tRNA Synthetases","Mt-aaRS Disorders","Hypertrophic Olivary Degeneration","Non-Ketotic Hyperglycinemia","Fish Odor Syndrome","Halitosis","Isolated Congenital Asplenia","Lambert Eaton (LEMS)","Biliary Atresia","STAG1 Gene Mutation","Coffin Lowry Syndrome","Borjeson-Forssman-Lehman Syndrome","Blau Syndrome","Arginase 1 Deficiency","HSPB8 Myopathy","Beta-Mannosidosis","TBX4 Syndrome","DHDDS Gene Mutations","MAND-MBD5-Associated Neurodevelopmental Disorder","Constitutional Mismatch Repair Deficiency (CMMRD)","SPATA5 Disorder","SPATA5L1 Related Disorder","Acrodysostosis","Multi-systematic Smooth Muscle Dysfunction Syndrome","CRELD1 (Cysteine Rich With EGF Like Domains 1)","GNB1 Syndrome","Pyruvate Dehydrogenase Complex Deficiency Disease","Beta Mannosidosis","Kbg Syndrome","Labrune Syndrome","Metachromatic Leukodystrophy (MLD)","Moyamoya Disease","OPHN1 Syndrome","Oculopharyngeal Muscular Dystrophy (OPMD)","TUBB3 Mutation","WOREE (WWOX-related Epileptic Encephalopathy","SCAR12","Skraban-Deardorff Syndrome","Hereditary Myopathy With Early Respiratory Failure",[985,986,987,988,989,696,990,991,703,992,664,993,994,995,866,875,996,997,655,998,999,663,1000,665,1001,654,1002,1003,878,1004,1005,881,882,1006,884,885,1007,1008,888,1009,1010,1011,937,1012,1013,1014,1015,1016,1017,1018,942,1019,1020,1021,947,948,1022,1023,1024,1025,1026],"Rare Diseases","Neglected Diseases","Orphan Diseases","Rare Disease Research","Registries","Ataxia","Cornelia de Lange Syndrome","Ataxia Telangiectasia","Batten Disease","Mucolipidosis IV","Klippel-Feil Syndrome","Undiagnosed","Uncommon Disease","Hypersomnia","Hyperacusis","Marinesco-Sjogren Syndrome","4p-\u002FWolf-Hirschhorn Syndrome","Narcolepsy","Wiedermann-Steiner Syndrome","Autoimmune\u002Finflammatory Syndrome Induced by Adjuvants (ASIA)","Hemophagocytic Lymphohistiocytosis (HLH)","Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD)","1p36 deletion syndrome","Jansen metaphyseal chondrodysplasia","Chronic recurrent multifocal osteomyelitis (CRMO)","Malan syndrome","Hereditary Sensory and Autonomic Neuropathy","Juvenile nephropathic cystinosis","Nephropathic infantile cystinosis","Ocular cystinosis","Kennedy disease","Spinal Bulbar Muscular Atrophy (SBMA)","SMC1A Truncated Mutations (causing loss of gene function)","Leigh syndrome","Mucolipidosis","Mitochondrial aminoacyl-tRNA synthetases (Mt-aaRS Disorders)","Shine Syndrome","Intestinal Bromhidrosis Syndrome","Fish odor syndrome","Autosomal recessive extra oral halitosis","CACNA1H mutation","Dimethylglycine dehydrogenase deficiency","2025-05-22",{"date":1029,"type":41},"2025-05-29",{"date":1031,"type":41},"2010-07",{"date":1033,"type":22},"2100-12",{"name":1035,"class":152},"Sanford Health",{"id":1037,"slug":1038,"hasResults":12,"nctId":1039,"briefTitle":1040,"officialTitle":1041,"acronym":4,"eligibilityCriteria":1042,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":1043,"enrollmentInfo":1044,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":1046,"conditions":1047,"keywords":1050,"overallStatus":430,"whyStopped":4,"lastUpdateSubmitDate":1055,"lastUpdatePostDateStruct":1056,"startDateStruct":1058,"completionDateStruct":1060,"leadSponsor":1062,"locationsCount":4},"100575768","ultrasound-and-electrophysiology-study-of-hand-in-systemic-sclerosis-patients-and-contributors-of-hand-dysfunction-100575768","NCT06776575","Ultrasound and Electrophysiology Study of Hand in Systemic Sclerosis Patients and Contributors of Hand Dysfunction","Musculoskeletal Ultrasound and Electrophysiological Evaluation of the Hand in Patients With Systemic Sclerosis: Relation to Hand Dysfunction and Quality of Life","Inclusion Criteria:\n\nAdult SSc Patients ( \\>18 yrs ) who are fulfilling the The EULAR\u002FACR 2013 classification criteria\n\nExclusion Criteria:\n\n1. Individuals with other autoimmune diseases (systemic lupus, sjogren syndrome, rheumatoid arthritis dermatomyositis, mixed connective tissue disease).\n2. Usage of drugs that can cause peripheral neuropathy and chronic alcohol abuse history.\n3. Presence of diabetes mellitus, thyroid dysfunction and renal failure","60 Years",{"count":1045,"type":22},45,"The goal of this research is to assess quality of life and hand function in systemic sclerosis patients via specific questionnaires, and to determine the main contributors to hand dysfunction via a thorough hand ultrasound study and electrophysiology study.",[32,1048,1049],"Hand Functionality","Quality of Life (QOL)",[1051,1052,1053,1054,113],"hand dysfunction","musculoskeletal ultrasound","electrophysiology","quality of life","2025-01-13",{"date":1057,"type":41},"2025-01-15",{"date":1059,"type":22},"2025-03-01",{"date":1061,"type":22},"2028-03-01",{"name":1063,"class":152},"Assiut University",{"id":1065,"slug":1066,"hasResults":12,"nctId":1067,"briefTitle":1068,"officialTitle":1069,"acronym":4,"eligibilityCriteria":1070,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":1071,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":1072,"conditions":1073,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":1079,"lastUpdatePostDateStruct":1080,"startDateStruct":1082,"completionDateStruct":1084,"leadSponsor":1086,"locationsCount":153},"100542214","rheumatology-diet-study-100542214","NCT06339957","Rheumatology Diet Study","Title of Study: Eating Habits and Symptom Severity in Autoimmune Diseases: a Patient Survey","Inclusion Criteria:\n\n* Adults (over 18 years old) patients\n* established UCF Health patients\n* diagnosed with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dermatomyositis\u002Fpolymyositis, Sjogren's Syndrome, systemic lupus erythematous, scleroderma, osteoarthritis, or fibromyalgia.\n\nExclusion Criteria:\n\n* UCF Students, Faculty or Staff\n* Children or Young Adults Under the age of 18\n* Adults over 65\n* Pregnant Women\n* Prisoners\n* Adults to Unable to Consent",{"count":564,"type":22},"This study aims to collect information on rheumatology patients' dietary habits, autoimmune disease activity, dietary changes, disease symptom improvements, and perceptions on their dietary habits and how it affects their autoimmune disease. The main objective is to see if rheumatology patients change their dietary habits after their diagnosis of an autoimmune disease and if it subjectively improved their disease symptoms. It will also look at rheumatology patients' expectations for their rheumatologist when it comes to dietary advice and what resources they used to choose their new dietary habits. The study also seeks to measure the interest that rheumatology patients have in pursuing dietary changes as a means of controlling the symptoms of their autoimmune disease. It is expected that patients who changed their eating habits to healthier diets such as a Mediterranean diet would report less severe autoimmune disease symptoms. There are limited dietary recommendations for the management of many rheumatological diseases, so this study seeks to assess rheumatology patients' willingness to try dietary modifications, what improvements they had, and why they decide to make these changes in light of limited information.",[1074,1075,369,169,257,256,1076,268,1077,32,1078],"Diet Habit","Rheumatologic Disease","Dermatomyositis\u002Fpolymyositis","Systemic Lupus Erythematous","Fibromyalgia","2024-12-03",{"date":1081,"type":41},"2024-12-06",{"date":1083,"type":41},"2024-03-01",{"date":1085,"type":22},"2025-07-01",{"name":1087,"class":152},"University of Central Florida"]